Products
Pipeline
Antisoma clinical development pipeline
| Drug | Type | Indication | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|
| ASA404 | Tumor-VDA | Non-small cell lung | |||
| Breast | |||||
| AS1413 | DNA intercalator | Secondary AML | |||
| AS1411 | DNA aptamer | AML | |||
| AS1409 | Fusion protein | Renal, Melanoma |
ASA404 is a Tumour-Vascular Disrupting Agent (Tumour-VDA) in phase III in first- and second-line NSCLC
AS1413 (amonafide L-malate) is a DNA intercalator in phase III in secondary AML
AS1411 is a DNA aptamer in phase II in AML
AS1409 is an antibody-cytokine fusion protein that has completed a phase I study in renal cell carcinoma and melanoma
Back to top